AKBA Relative Valuation
AKBA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AKBA is overvalued; if below, it's undervalued.
Historical Valuation
Akebia Therapeutics Inc (AKBA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -3.84. The fair price of Akebia Therapeutics Inc (AKBA) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.57 USD , Akebia Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：1.57
Fair
Undervalued
81.54
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Akebia Therapeutics Inc. (AKBA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.02. The thresholds are as follows: Strongly Undervalued below -3.85, Undervalued between -3.85 and -2.43, Fairly Valued between 0.40 and -2.43, Overvalued between 0.40 and 1.81, and Strongly Overvalued above 1.81. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
16.39
EV/EBIT
Akebia Therapeutics Inc. (AKBA) has a current EV/EBIT of 16.39. The 5-year average EV/EBIT is 5.40. The thresholds are as follows: Strongly Undervalued below -168.68, Undervalued between -168.68 and -81.64, Fairly Valued between 92.45 and -81.64, Overvalued between 92.45 and 179.49, and Strongly Overvalued above 179.49. The current Forward EV/EBIT of 16.39 falls within the Historic Trend Line -Fairly Valued range.
1.62
PS
Akebia Therapeutics Inc. (AKBA) has a current PS of 1.62. The 5-year average PS is 1.75. The thresholds are as follows: Strongly Undervalued below -0.29, Undervalued between -0.29 and 0.73, Fairly Valued between 2.77 and 0.73, Overvalued between 2.77 and 3.79, and Strongly Overvalued above 3.79. The current Forward PS of 1.62 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Akebia Therapeutics Inc. (AKBA) has a current P/OCF of 0.00. The 5-year average P/OCF is -6.29. The thresholds are as follows: Strongly Undervalued below -49.58, Undervalued between -49.58 and -27.93, Fairly Valued between 15.36 and -27.93, Overvalued between 15.36 and 37.01, and Strongly Overvalued above 37.01. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
19.83
P/FCF
Akebia Therapeutics Inc. (AKBA) has a current P/FCF of 19.83. The 5-year average P/FCF is 4.75. The thresholds are as follows: Strongly Undervalued below -63.32, Undervalued between -63.32 and -29.28, Fairly Valued between 38.79 and -29.28, Overvalued between 38.79 and 72.83, and Strongly Overvalued above 72.83. The current Forward P/FCF of 19.83 falls within the Historic Trend Line -Fairly Valued range.
Akebia Therapeutics Inc (AKBA) has a current Price-to-Book (P/B) ratio of 10.01. Compared to its 3-year average P/B ratio of 1.38 , the current P/B ratio is approximately 625.90% higher. Relative to its 5-year average P/B ratio of 1.99, the current P/B ratio is about 402.13% higher. Akebia Therapeutics Inc (AKBA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -19.95%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -53.94% , the current FCF yield is about -100.00% lower.
10.14
P/B
Median3y
1.38
Median5y
1.99
7.72
FCF Yield
Median3y
-19.95
Median5y
-53.94
Competitors Valuation Multiple
The average P/S ratio for AKBA's competitors is 83.40, providing a benchmark for relative valuation. Akebia Therapeutics Inc Corp (AKBA) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 57.01%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AKBA decreased by 16.32% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 37.43M to 58.77M.
The secondary factor is the P/E Change, contributed 28.39%to the performance.
Overall, the performance of AKBA in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Akebia Therapeutics Inc (AKBA) currently overvalued or undervalued?
What is Akebia Therapeutics Inc (AKBA) fair value?
How does AKBA's valuation metrics compare to the industry average?
What is the current P/B ratio for Akebia Therapeutics Inc (AKBA) as of Dec 05 2025?
What is the current FCF Yield for Akebia Therapeutics Inc (AKBA) as of Dec 05 2025?
What is the current Forward P/E ratio for Akebia Therapeutics Inc (AKBA) as of Dec 05 2025?